Recommendation of the President – Yervoy (ipilimumab)
On 3 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 189/2025 on the reimbursement of the medicinal product Yervoy (ipilimumab) under the B.4. drug program. “Treatment of patients with colorectal cancer (ICD-10: C18-C20)”